allogeneic sibling umbilical cord blood mononuclear cells

Allogeneic sibling umbilical cord blood mononuclear cells (UCB-MNCs) are an investigational cell therapy being evaluated for the treatment of pediatric neurological disorders, including cerebral palsy and moderate-to-severe hypoxic-ischemic encephalopathy (HIE). The therapy involves the intravenous infusion of mononuclear cells derived from a sibling's umbilical cord blood, typically administered alongside peri-infusion immunosuppression (such as cyclosporine) to mitigate the risk of graft-versus-host disease or rejection. The therapeutic mechanism is hypothesized to involve paracrine signaling, where the infused cells secrete neurotrophic factors and anti-inflammatory cytokines that modulate the immune response and stimulate endogenous neural repair and neuroprotection. Clinical evaluation, such as the safety study conducted at Kochi Medical School Hospital, has focused on children aged 1–6 years to assess the feasibility and safety of this allogeneic approach.

Other names

sibling umbilical cord blood mononuclear cellsallogeneic sibling UCB-MNCs